TROXIPIDE

Details

Stereochemistry	RACEMIC
Molecular Formula	C15H22N2O4
Molecular Weight	294.3462
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC(=CC(OC)=C1OC)C(=O)NC2CCCNC2

InChI

InChIKey=YSIITVVESCNIPR-UHFFFAOYSA-N

InChI=1S/C15H22N2O4/c1-19-12-7-10(8-13(20-2)14(12)21-3)15(18)17-11-5-4-6-16-9-11/h7-8,11,16H,4-6,9H2,1-3H3,(H,17,18)

HIDE SMILES / InChI

Molecular Formula	C15H22N2O4
Molecular Weight	294.3462
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://www.kyorin-pharm.co.jp/prodinfo/medicine/pdf/Aplace.pdf
Curator's Comment: description was created based on several sources, including, http://www.ncbi.nlm.nih.gov/pubmed/21127703, http://sciencedomain.org/abstract/1515

Troxipide is a gastric cytoprotective agent used for the treatment of gastritis and gastric uclers in Japan, India, China and South Korea. Troxipide has a mode of action different from that for other anti-gastric agents: it does not inhibit acid secretion and does not have acid neutralizing activity. It exerts its activity by increasing mucus production, cytoprotective prostaglandin secretion, regeneration of collagen fibers, reducing inflammatory mediator induced neutrophil migration and reactive oxygen species generation in gastric mucosa, enhancing gastric mucosal metabolism and microcirculation.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
mucus secretion 8 Target ID: GO:0070254 Sources: http://sciencedomain.org/abstract/1515	Activator 1447
prostaglandin secretion 19 Target ID: GO:0032310 Sources: http://sciencedomain.org/abstract/1515	Activator 1447
collagen fibril organization 1 Target ID: GO:0030199 Sources: http://sciencedomain.org/abstract/1515	Activator 1447
neutrophil migration 2 Target ID: GO:1990266 Sources: http://sciencedomain.org/abstract/1515	Inhibitor 8504
reactive oxygen species biosynthetic process 41 Target ID: GO:1903409 Sources: http://sciencedomain.org/abstract/1515	Inhibitor 8504
gastric mucosal blood circulation 6 Target ID: GO:1990768 Sources: http://sciencedomain.org/abstract/1515	Activator 1447

Conditions

Condition	Modality	Targets	Highest Phase	Product
Gastric ulcer 74 Sources: http://www.kyorin-pharm.co.jp/prodinfo/medicine/pdf/Aplace.pdf	Primary		Approved 8583	APLACE Approved Use Gastric ulcers, Amelioration of gastric mucosal lesions (erosion, hemorrhage, redness and edema) in the following diseases: acute gastritis, acute exacerbation stage of chronic gastritis. Launch Date 1991
Acute and chronic gastritis 1 Sources: http://www.kyorin-pharm.co.jp/prodinfo/medicine/pdf/Aplace.pdf	Primary		Approved 8583	APLACE Approved Use Gastric ulcers, Amelioration of gastric mucosal lesions (erosion, hemorrhage, redness and edema) in the following diseases: acute gastritis, acute exacerbation stage of chronic gastritis. Launch Date 1991

C_max

Value	Dose	Co-administered	Analyte	Population
0.84 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/230109_2329015C1100_1_013_1F.pdf#page=16	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		TROXIPIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.09 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/230109_2329015C1100_1_013_1F.pdf#page=16	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		TROXIPIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
7.13 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/230109_2329015C1100_1_013_1F.pdf#page=16	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		TROXIPIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
7.94 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/230109_2329015C1100_1_013_1F.pdf#page=16	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		TROXIPIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
7.4 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/230109_2329015C1100_1_013_1F.pdf#page=16	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		TROXIPIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
7 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/230109_2329015C1100_1_013_1F.pdf#page=16	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		TROXIPIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
100% OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/230109_2329015C1100_1_013_1F.pdf#page=17			TROXIPIDE serum	Homo sapiens

Doses

Dose	Population	Adverse events
100 mg 3 times / day multiple, oral Recommended\|Highest studied dose Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://journaljammr.com/index.php/JAMMR/article/view/13470/24697	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://journaljammr.com/index.php/JAMMR/article/view/13470/24697	Other AEs: Fatigue, Headache... Other AEs: Fatigue (grade 1-2, 0.07%) Headache (grade 1-2, 0.07%) Syncope (grade 1-2, 0.07%) Malaise (grade 1-2, 0.07%) Chest pain (grade 1-2, 0.07%) Belching (grade 1-2, 0.14%) Abdominal distension (grade 1-2, 0.07%) Constipation (grade 1-2, 0.14%) Esophageal acid reflux (grade 1-2, 0.07%) Nausea (grade 1-2, 0.07%) Vomiting (grade 1-2, 0.07%) ALT increased (grade 1-2, 0.07%) Sources: https://journaljammr.com/index.php/JAMMR/article/view/13470/24697
100 mg 3 times / day multiple, oral Recommended\|Highest studied dose Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21127703/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/21127703/	Other AEs: Constipation, Headache... Other AEs: Constipation (grade 1-2, 5.6%) Headache (grade 1-2, 5.6%) Sources: https://pubmed.ncbi.nlm.nih.gov/21127703/

AEs

AE	Significance	Dose	Population
ALT increased	grade 1-2, 0.07%	100 mg 3 times / day multiple, oral Recommended\|Highest studied dose Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://journaljammr.com/index.php/JAMMR/article/view/13470/24697	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://journaljammr.com/index.php/JAMMR/article/view/13470/24697
Abdominal distension	grade 1-2, 0.07%	100 mg 3 times / day multiple, oral Recommended\|Highest studied dose Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://journaljammr.com/index.php/JAMMR/article/view/13470/24697	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://journaljammr.com/index.php/JAMMR/article/view/13470/24697
Chest pain	grade 1-2, 0.07%	100 mg 3 times / day multiple, oral Recommended\|Highest studied dose Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://journaljammr.com/index.php/JAMMR/article/view/13470/24697	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://journaljammr.com/index.php/JAMMR/article/view/13470/24697
Esophageal acid reflux	grade 1-2, 0.07%	100 mg 3 times / day multiple, oral Recommended\|Highest studied dose Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://journaljammr.com/index.php/JAMMR/article/view/13470/24697	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://journaljammr.com/index.php/JAMMR/article/view/13470/24697
Fatigue	grade 1-2, 0.07%	100 mg 3 times / day multiple, oral Recommended\|Highest studied dose Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://journaljammr.com/index.php/JAMMR/article/view/13470/24697	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://journaljammr.com/index.php/JAMMR/article/view/13470/24697
Headache	grade 1-2, 0.07%	100 mg 3 times / day multiple, oral Recommended\|Highest studied dose Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://journaljammr.com/index.php/JAMMR/article/view/13470/24697	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://journaljammr.com/index.php/JAMMR/article/view/13470/24697
Malaise	grade 1-2, 0.07%	100 mg 3 times / day multiple, oral Recommended\|Highest studied dose Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://journaljammr.com/index.php/JAMMR/article/view/13470/24697	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://journaljammr.com/index.php/JAMMR/article/view/13470/24697
Nausea	grade 1-2, 0.07%	100 mg 3 times / day multiple, oral Recommended\|Highest studied dose Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://journaljammr.com/index.php/JAMMR/article/view/13470/24697	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://journaljammr.com/index.php/JAMMR/article/view/13470/24697
Syncope	grade 1-2, 0.07%	100 mg 3 times / day multiple, oral Recommended\|Highest studied dose Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://journaljammr.com/index.php/JAMMR/article/view/13470/24697	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://journaljammr.com/index.php/JAMMR/article/view/13470/24697
Vomiting	grade 1-2, 0.07%	100 mg 3 times / day multiple, oral Recommended\|Highest studied dose Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://journaljammr.com/index.php/JAMMR/article/view/13470/24697	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://journaljammr.com/index.php/JAMMR/article/view/13470/24697
Belching	grade 1-2, 0.14%	100 mg 3 times / day multiple, oral Recommended\|Highest studied dose Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://journaljammr.com/index.php/JAMMR/article/view/13470/24697	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://journaljammr.com/index.php/JAMMR/article/view/13470/24697
Constipation	grade 1-2, 0.14%	100 mg 3 times / day multiple, oral Recommended\|Highest studied dose Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://journaljammr.com/index.php/JAMMR/article/view/13470/24697	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://journaljammr.com/index.php/JAMMR/article/view/13470/24697
Constipation	grade 1-2, 5.6%	100 mg 3 times / day multiple, oral Recommended\|Highest studied dose Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21127703/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/21127703/
Headache	grade 1-2, 5.6%	100 mg 3 times / day multiple, oral Recommended\|Highest studied dose Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21127703/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/21127703/

PubMed

Title	Date	PubMed
Troxipide in the management of gastritis: a randomized comparative trial in general practice.	2010	21127703

Patents

Sample Use Guides

In Vivo Use Guide

The usual adult dosage for oral use is 100 mg of troxipide (one tablet or 0.5 g of fine granules) three times daily after meals.

Route of Administration: Oral

In Vitro Use Guide

Incubation of neutrophils with 10(-6) to 10(4) M troxipide caused inhibition of recombinant interleukin-8-induced migration.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 06:52:54 GMT 2025` Edited by `admin` on `Wed Apr 02 06:52:54 GMT 2025`
Record UNII	W6QJX1Q00Z
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TROXIPIDE

Official Name

English

APLACE

Preferred Name

English

TROXIPIDE [MART.]

Common Name

English

TROXIPIDE [MI]

Common Name

English

TROXIPIDE [JAN]

Common Name

English

troxipide [INN]

Common Name

English

(±)-3,4,5-TRIMETHOXY-N-3-PIPERIDYLBENZAMIDE

Systematic Name

English

Troxipide [WHO-DD]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QA02BX11